Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis.
The use of vitamin D analogues for the treatment of chronic plaque psoriasis is well documented. Of importance now is their comparability and compatibility with other established treatments for psoriasis. This paper reviews five studies with calcitriol 3 microg g(-1) ointment (Silkis ointment, Galderma Laboratories). Calcitriol applied twice daily was found to be as effective as short-contact dithranol in terms of global improvement and PASI scores. However, patients favoured calcitriol over dithranol when both quality of life and treatment acceptability were assessed. Two studies provide evidence of the benefit of combining calcitriol with other antipsoriatic therapies. Combination with ultraviolet (UV) B phototherapy proved as effective as UVB alone over an 8-week period; however, the combination had a radiation dose-sparing effect, thus reducing the risk of adverse events. Likewise, calcitriol combined with betamethasone valerate (each applied separately, once daily) was as efficacious as twice-daily betamethasone, thereby achieving a corticosteroid-sparing effect. Finally, two studies confirm that calcitriol 3 microg g(-1) ointment can be used safely in patients with psoriasis of the head and confirm the high level of clinical efficacy achieved with this compound.
Kowalzick
L
L
Department of Dermatology and Allergology, Vogtland-Klinikum Plauen GmbH, Germany. lutz.kowalzick@t-online.de
D000287:Administration, Topical; D000328:Adult; D000875:Anthralin / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001624:Betamethasone Valerate / Q000627:therapeutic use; D002117:Calcitriol / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*; D014467:Ultraviolet Therapy
D000893:Anti-Inflammatory Agents; D001624:Betamethasone Valerate; D002117:Calcitriol; D000875:Anthralin